CAS No.60-15-1,alpha-methylphenethylamine Suppliers

Products Categories

Pharmaceutical (18)
Others (7)
Basic Inorganic Chemicals (2)

Basic Information

Molecular Structure:
CAS No.:	60-15-1
Name:	alpha-methylphenethylamine
Article Data:	117

Formula:	C9H13N
Molecular Weight:	135.209
Synonyms:	2-Aminopropylbenzene;3-Phenyl-2-propylamine;3-Phenyl-2-propanamine;1-Phenyl-2-propanamine;
Density:	0.958g/cm3
Boiling Point:	234.7oC at 760 mmHg
Flash Point:	98.7oC
PSA:	26.02000
LogP:	2.27660

Downstream Products

354-38-1

139-68-4

698-87-3

103-79-7

Country:
Business Type:
All

Lab/Research institutions

Trading Company

Manufacturers

Other
Certificate:
Manufacturer

Enterprise Authentication

ISO

GMP

FDA

HALAL

Display:default sort
Suppiers of more reward points first

New supplier

Total:26 Page 1 of 1 1

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 60-15-1

Chemistry

Molecular Structure:

Molecular Formula: C₉H₁₃N
Molecular Weight: 135.2062
IUPAC Name: 1-Phenylpropan-2-amine
Synonyms of Amphetamine (CAS NO.300-62-9): Benzeneethanamine, alpha-methyl- ; Benzeneethanamine, alpha-methyl-, (+-)- ; Phenethylamine, alpha-methyl- ; alpha-Methylphenethylamine ; Amphetamine, its salts, optical isomers, and salts of its optical isomers ; DEA No. 1100
CAS NO: 300-62-9
Classification Code: Adrenergic agents ; Adrenergic uptake inhibitors ; Autonomic Agents ; Central Nervous System Agents ; Central nervous system stimulants ; Dopamine agents ; Dopamine uptake inhibitors ; Drug / Therapeutic Agent ; Human Data ; Mutation data ; Neurotransmitter Agents ; Neurotransmitter Uptake Inhibitors ; Peripheral Nervous System Agents ; Reproductive Effect ; Sympathomimetics
Index of Refraction: 1.527
Molar Refractivity: 43.92 cm³
Molar Volume: 142.8 cm³
Surface Tension: 36.1 dyne/cm
Density: 0.946 g/cm³
Flash Point: 87.4 °C
Enthalpy of Vaporization: 43.77 kJ/mol
Boiling Point: 201.5 °C at 760 mmHg
Vapour Pressure: 0.307 mmHg at 25°C

History

1. Amphetamine (CAS NO.300-62-9) was first synthesized in 1887 by the Romanian Lazr Edeleanu in Berlin, Germany.He named the compound phenylisopropylamine.
2. From 1933 or 1934 Smith, Kline and French began selling the volatile base form of the drug as an inhaler under the trade name Benzedrine.
3. The related compound methamphetamine was first synthesized from ephedrine in Japan in 1918 by chemist Akira Ogata, via reduction of ephedrine using red phosphorus and iodine. The German military was notorious for their use of methamphetamine in World War II.
4. In 1997 and 1998,researchers at Texas A&M University claimed to have found amphetamine and methamphetamine in the foliage of two Acacia species native to Texas.
5. Amphetamines were still in use in the US Air Force as of 2003 to combat pilot fatigue.

Uses

Amphetamine (CAS NO.300-62-9) (amfetamine (INN)) is a psychostimulant drug that is known to produce increased wakefulness and focus in association with decreased fatigue and appetite. It is also used to treat symptoms of traumatic brain injury and the daytime drowsiness symptoms of narcolepsy, Postural Orthostatic Tachycardia Syndrome and chronic fatigue syndrome. It is used by some college and high-school students as a study and test-taking aid. It has been, and is still, used by militaries around the world.Amphetamine is also used by some professional,collegiate and high school athletes for its strong stimulant effect.

Toxicity Data With Reference

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
dog	LDLo	subcutaneous	20mg/kg (20mg/kg)		"Structure et Activite Pharmacodyanmique des Medicaments du Systeme Nerveux Vegetatif," Bovet, D., and F. Bovet-Nitti, New York, S. Karger, 1948Vol. -, Pg. 149, 1948.
guinea pig	LDLo	oral	200mg/kg (200mg/kg)	BEHAVIORAL: TREMOR BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: EXCITEMENT	Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales. Vol. 128, Pg. 680, 1938.
guinea pig	LDLo	parenteral	20mg/kg (20mg/kg)	BEHAVIORAL: TREMOR BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: EXCITEMENT	Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales. Vol. 128, Pg. 680, 1938.
guinea pig	LDLo	subcutaneous	20mg/kg (20mg/kg)	BEHAVIORAL: TREMOR BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: EXCITEMENT	Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales. Vol. 128, Pg. 680, 1938.
mammal (species unspecified)	LD50	intraperitoneal	65mg/kg (65mg/kg)		Biochimie. Vol. 63, Pg. 495, 1981.
mammal (species unspecified)	LD50	oral	135mg/kg (135mg/kg)		Biochimie. Vol. 63, Pg. 495, 1981.
man	LDLo	unreported	2206ug/kg (2.206mg/kg)		"Poisoning; Toxicology, Symptoms, Treatments," 2nd ed., Arena, J.M., Springfield, IL, C.C. Thomas, 1970Vol. 2, Pg. 73, 1970.
monkey	LDLo	subcutaneous	20mg/kg (20mg/kg)		"Structure et Activite Pharmacodyanmique des Medicaments du Systeme Nerveux Vegetatif," Bovet, D., and F. Bovet-Nitti, New York, S. Karger, 1948Vol. -, Pg. 149, 1948.
mouse	LD50	intraperitoneal	5500ug/kg (5.5mg/kg)		Archives Internationales de Pharmacodynamie et de Therapie. Vol. 161, Pg. 206, 1966.
mouse	LD50	intravenous	15mg/kg (15mg/kg)		Archives Internationales de Pharmacodynamie et de Therapie. Vol. 146, Pg. 392, 1963.
mouse	LD50	oral	21mg/kg (21mg/kg)		Arzneimittel-Forschung. Drug Research. Vol. 23, Pg. 810, 1973.
mouse	LD50	subcutaneous	15mg/kg (15mg/kg)		Federation Proceedings, Federation of American Societies for Experimental Biology. Vol. 4, Pg. 139, 1945.
mouse	LD50	unreported	8800ug/kg (8.8mg/kg)		Acta Physiologica Academiae Scientiarum Hungaricae. Vol. 32, Pg. 377, 1967.
rabbit	LDLo	intravenous	25mg/kg (25mg/kg)		"Structure et Activite Pharmacodyanmique des Medicaments du Systeme Nerveux Vegetatif," Bovet, D., and F. Bovet-Nitti, New York, S. Karger, 1948Vol. -, Pg. 149, 1948.
rabbit	LDLo	subcutaneous	20mg/kg (20mg/kg)		"Structure et Activite Pharmacodyanmique des Medicaments du Systeme Nerveux Vegetatif," Bovet, D., and F. Bovet-Nitti, New York, S. Karger, 1948Vol. -, Pg. 149, 1948.
rat	LD50	oral	30mg/kg (30mg/kg)		Arzneimittel-Forschung. Drug Research. Vol. 23, Pg. 810, 1973.
rat	LD50	subcutaneous	180mg/kg (180mg/kg)	BEHAVIORAL: EXCITEMENT	Journal of Pharmacology and Experimental Therapeutics. Vol. 85, Pg. 119, 1945.
rat	LDLo	intraperitoneal	23mg/kg (23mg/kg)		Naunyn-Schmiedeberg's Archiv fuer Experimentelle Pathologie und Pharmakologie. Vol. 195, Pg. 647, 1940.
rat	LDLo	intravenous	20mg/kg (20mg/kg)		"Structure et Activite Pharmacodyanmique des Medicaments du Systeme Nerveux Vegetatif," Bovet, D., and F. Bovet-Nitti, New York, S. Karger, 1948Vol. -, Pg. 101, 1948.

Safety Profile

Poison by ingestion, subcutaneous, intravenous, and intraperitoneal routes. Human systemic effects by ingestion: excitement, changes in heart rate and sweating. When heated to decomposition it emits very toxic fumes of NO_x. See other amphetamine entries.

Specification

Contraindications
1. If patients taking MAOI antidepressants amphetamine may cause a life-threatening complication
2Amphetamine elevates cardiac output and blood pressure making it dangerous for use by patients who has a history of heart disease or hypertension.
3. Amphetamine (CAS NO.300-62-9) should not be used by patients with a history of glaucoma.
4. As amphetamine has been shown to pass through into breast milk, mothers taking amphetamine are advised to avoid breastfeeding during their course of treatment.
5. Amphetamine can inhibit the effects of the contraceptive pill .